Search results
She's been waiting for a liver donation for over a year: 'I know God has a plan for me, but its...
CBS 6 Richmond· 6 days agoMother and wife Tina Doane was diagnosed with Stage 4 cirrhosis of the liver and given two years to live if she didn't ...
High levels of novel biomarker GDF15 in steatotic liver patients linked to increased liver cancer...
Medical Xpress· 7 days agoThe findings are published in the journal Alimentary Pharmacology & Therapeutics. Steatotic (fatty) liver disease is on the rise in many countries around the world. A rise in steatotic liver ...
Seladelpar Shows Clinically Meaningful Improvements in PBC
Medscape· 2 days agoSeladelpar, an investigational selective peroxisome proliferator-activated receptor delta agonist, achieves both biochemical and clinically meaningful improvements in pruritus and liver injury ...
'Dramatic' Phase 2 Results for Survodutide in MASH, Fibrosis
Medscape· 1 day agoSurvodutide, a dual agonist that targets glucagon and glucagon-like peptide 1 receptors, led to a...
Boehringer Ingelheim's survodutide shows breakthrough improvement in liver fibrosis with no...
Benzinga· 6 days agoNews builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) versus placebo
Tirzepatide Shows Improvements in MASH Resolution, Fibrosis
Medscape· 3 days agoEncouraging phase 2 results of tirzepatide in the resolution of MASH and improvement in fibrosis...
Baytown worship pastor Ke'Erron encourages others while battling medical problems
KRIV via Yahoo News· 22 hours agoKe'Erron is a worship pastor at Faith Family Church in Baytown. He is encouraging others who are facing health and life challenges through his music and message, all while battling his own health problems.
Eli Lilly Runs Up 49% With Expectations For Weight-Loss Sales To Triple
Investor's Business Daily· 1 day agoRevenue from Eli Lilly's weight-loss drug is expected to triple over the next five years to over $50...
FDA OKs Iqirvo, First-in-Class PPAR Treatment for PBC
Medscape· 2 days agoIqirvo (elafibranor) is indicated for adults with primary biliary cholangitis who do not respond to or cannot tolerate ursodeoxycholic acid.
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals | The Motley Fool
The Motley Fool· 3 days agoViking Therapeutics (VKTX 0.70%) and Madrigal Pharmaceuticals (MDGL 4.31%) are highly prominent...